Abnova (Taiwan) Corporation (TPE:4133)

Market Cap	1.62B
Revenue (ttm)	360.75M
Net Income (ttm)	48.51M
Shares Out	60.55M
EPS (ttm)	0.80
PE Ratio	33.49
Forward PE	n/a
Dividend	0.90 (3.33%)
Ex-Dividend Date	Jun 16, 2025

Volume	140,366
Average Volume	268,851
Open	27.05
Previous Close	27.05
Day's Range	26.65 - 27.15
52-Week Range	21.70 - 35.10
Beta	0.19
RSI	40.75
Earnings Date	Aug 8, 2025

About Abnova (Taiwan)

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company’s products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4133

Financial Performance

In 2024, Abnova (Taiwan)'s revenue was 355.26 million, a decrease of -7.01% compared to the previous year's 382.05 million. Earnings were 61.61 million, an increase of 41.05%.